Ease-react program
Active Other Transaction Agreement Awarded Last action
- Contract number
- 140D042490004
- Awardee
-
Mayo Clinic UEI Y2K4F9RPRRG7 Part of Mayo Clinic
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $27,142,018
Award facts
- Contract value 63% obligated
-
- $27,142,017.91 Current, with exercised options
- $42,805,278.12 Potential, with all options
- Completion date 35% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institutes of Health Department of Health and Human Services
- NAICS code
- Not on record
- PSC
- AJ12 General Science And Technology R&D Services; General Science And Technology; Applied Research
- Competition
- Competed Program Solicitation
- Pricing
- Other
- Place of performance
- Rochester, MN 55905, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $27,142,018 |
About this award
The National Institutes of Health awarded an Other Transaction Agreement to Mayo Clinic on September 16, 2024, for the EASE-REACT program (Engage Assess SecretE: A Platform for Treating Chronic Inflammation), a biomedical device development effort valued at $42.8 million with performance through September 15, 2030. The OTA sits outside the FAR and operates under ARPA-H authority.
The program develops an implantable device platform that functions as a living pharmacy, using engineered cells to secrete therapeutic proteins on demand to treat chronic inflammation. Mayo Clinic serves as the lead institution coordinating a multi-site research consortium. Work is performed in Rochester, Minnesota, with subordinate research execution across affiliated institutions.
The consortium includes Case Western Reserve University (oxygen sensing and cell cartridge integration), the University of California, Davis (light-based genetic circuits for therapeutic antibody production control), the University of Minnesota (molecular construct design, cell engineering, and cellular chassis development), the University of Texas at Dallas (assay chemistry and biosensor validation in human subjects), SUNY Binghamton (oxygen-generating microelectrodes), Enlisense LLC (wearable sensor manufacturing and integration), and Sersense Inc. The program spans five technical areas: target dose confirmation through animal studies, on-chip oxygen generation and monitoring, optogenetic circuits for inducible antibody production, wearable biosensor development for therapeutic monoclonal antibody and inflammatory biomarker detection in sweat, and IND-enabling activities supporting clinical translation.
Subcontract awards to consortium members flowed between November 2024 and December 2025, with task orders addressing molecular engineering, cell culture optimization, bioelectronics fabrication, sweat-based biomarker assay development, and clinical validation protocols. The effort emphasizes light-controlled therapeutic production, cellular survival within implantable devices across microenvironmental conditions, and longitudinal correlation of biomarkers between sweat and serum in human cohorts with chronic inflammatory conditions.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Case Western Reserve University | $320,695 | |
| University Of California, Davis | $542,324 | |
| Enlisense LIMITED Liability Company | $1,093,666 | |
| Regents Of The University Of Minnesota | $1,776,846 | |
| University Of Texas At Dallas | $287,689 | |
| The Research Foundation For The State University Of New York | $302,023 | |
| Regents Of The University Of Minnesota | $1,763,581 | |
| Case Western Reserve University | $383,367 | |
| University Of California, Davis | $542,044 | |
| University Of Texas At Dallas | $280,659 | |
| Sersense Inc. | $472,709 | |
| The Research Foundation For The State University Of New York | $298,157 | |
| Enlisense LIMITED Liability Company | $846,680 |
Show all 13
Quick answers
Who was awarded contract 140D042490004?
140D042490004 was awarded to Mayo Clinic by Interior Business Center (Office of Policy Management and Budget) on September 16, 2024.
How much is contract 140D042490004 worth?
The government has obligated $27,142,018 on 140D042490004. Its potential value, with all options, is $42,805,278.
Which agency awarded contract 140D042490004?
Interior Business Center (Office of Policy Management and Budget) awarded 140D042490004, with funding from National Institutes of Health (Department of Health and Human Services).
Was contract 140D042490004 competed?
The extent of competition for 140D042490004 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award